Microsoft Word - Candidates for 2017 ERP of the Year

242

AOAC RESEARCH INSTITUTE  Expert Review Panel Chair Report for Gluten Assays  Page 4 of 5 

MEETING MINUTES

I.

Welcome and Introductions  The Expert Review Panel Chair Terry Koerner (Health Canada) and Jonathan Goodwin  (AOAC Interim Executive  Director) welcomed the Expert Review Panel members, initiated introductions, and discussed with the panel  the goal of the meeting.  Deborah McKenzie presented a brief overview of AOAC Volunteer Policies, Volunteer Acceptance Agreement  and Expert Review Panel Policies and Procedures which included Volunteer Conflicts of Interest, Policy on the  Use of the Association, Name, Initials, Identifying Insignia, Letterhead, and Business Cards, Antitrust Policy  Statement and Guidelines, and the Volunteer Acceptance Form (VAF).  All members of the ERP were required  to submit and sign the Volunteer Acceptance Form.  In addition, she also presented an overview of the ERP  process including meeting logistics, consensus, First Action to Final Action requirements, and documentation.  Review of Methods  The Expert Review Panel Co‐Chair Dr. Terry Koerner discussed the methods to be reviewed and the ERP  members presented a review and discussed AOAC OMA 2014.03 Gluten in Rice Flour and Rice‐Based Food  Products, First Action 2014. The method author, organization representative, Michael Prinster of Romer Labs  was present and able to address questions and concerns of the ERP members.  By consensus, the ERP  presented the following motions for OMA 2014.03. 1 MOTION:  Motion by Popping; Second by Don, to move 2014.03 for AOAC Final Action consideration status.   Consensus demonstrated by: (Unanimous) in favor, 0 opposed, and 0 abstentions. Motion Passed. The ERP members presented a review and discussed the proposed modification 2  of AOAC Official Method  2012.01: Gliadin as a Measure of Gluten in Rice and Corn Based Foods, Final Action 2017. The method author  Dr. Markus Lacorn of R‐Biopharm was present and able to address questions and concerns of the ERP  members.    Background of the proposed modification:  The AOAC validated ELISA assay RIDASCREEN® Gliadin R7001 (OMA first action 2012.01) use a washing buffer  which contains thimerosal (also known as thiomersal), a mercury containing preserving agent. Since the use  and/or the disposal of mercury‐containing liquids is heavily regulated in many countries or even prohibited in  some countries and in order to protect the environment, R‐Biopharm AG would like to substitute thimerosal in  the washing buffer by the mercury‐free preserving agent bronidox L.  The experiments showed that there is no  significant difference in stability and functionality between the buffer with thimerosal and with bronidox L.  Most importantly, the mean obtained concentrations for the used control samples did not show a significant  difference between thimerosal and bronidox L containing wash buffer. By consensus, the ERP presented the  following motions for OMA 2012.01.    MOTION:  Motion by Boison; Second by Koerner, to recommend the modification of the wash solution to be  considered a Minor Modification and will not affect the AOAC Final Action status.    Consensus demonstrated by: (Unanimous) in favor, 0 opposed, and 0 abstentions. Motion Passed.

II. Review of AOAC Volunteer Policies & Expert Review Panel Process Overview and Guidelines  

III.

1  Attachment 1: Method Author Presentation for AOAC OMA 2014.03  2  Attachment 2: Method Author Documentation for the Modification of AOAC OMA 2012.01     Attachment 3: AOAC ERP Presentation of Motions  03/12/2018